Minhua Chu/LinkedIn
Aug 6, 2025, 09:00
Minhua Chu: The First Clinical Trial Combining Ivonescimab With an ADC has Received Approval
Minhua Chu, Managing Partner at TransitionValue Partner, shared a post on X:
“Therapeutics’s B7H3 ADC YL201, in combination with Akeso‘s PD-1/VEGF bispecific antibody ivonescimab, has received approval for a clinical trial application for multiple solid tumors.
This marks the first clinical trial combining ivonescimab with an ADC.
Last month, after Akeso‘s first bispecific ADC drug, targeting TROP-2/Nectin-4 (AK146D1), completed its first Phase 1 dosing in Australia, the company introduced the concept of ‘IO+ADC’ 2.0.
YL201 has initiated two Phase 3 clinical trials.”
More posts featuring Minhua Chu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 6, 2025, 08:53
Aug 6, 2025, 08:52
Aug 6, 2025, 08:48
Aug 6, 2025, 08:33